Drug Trial Radar · NCT00097786
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Last checked: Nov 20, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,306
Actual
Start
Jan 2002
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 1, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Valsartan 160 mg + nateglinide 60 mgDrug
The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Valsartan 160 mg + nateglinide placeboDrug
The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Nateglinide 60 mg + valsartan placeboDrug
The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Valsartan placebo + nateglinide placeboDrug
The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartanTime frame: Mean patient duration of 4.2 years
- Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartanTime frame: Mean patient duration of 5.6 years
- Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartanTime frame: Mean patient duration of 5.8 years
- Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinideTime frame: Mean patient duration of 4.2 years
- Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinideTime frame: Mean patient duration of 5.6 years
- Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinideTime frame: Mean patient duration of 5.8 years
Locations
38 sites in 38 countries. Site status is shown where the registry gives one.
Site not named
Multiple Locations, New Jersey
Site not named
Investigative Site, Argentina
Site not named
Investigative Site, Australia
Site not named
Multiple Locations, Austria
Site not named
Investigative Site, Belgium
Site not named
Investigative Site, Brazil
Site not named
Investigative Site, Canada
Site not named
Investigative Site, Chile
Site not named
Investigative Site, China
Site not named
Investigative Site, Colombia
Site not named
Investigative Site, Czechia
Site not named
Investigative Site, Denmark
Site not named
Investigative Site, Ecuador
Site not named
Investigative Site, Finland
Site not named
Investigative Site, France
Site not named
Investigative Site, Germany
Site not named
Investigative Site, Greece
Site not named
Investigative Site, Guatemala
Site not named
Investigative Site, Hong Kong
Site not named
Investigative Site, Hungary
Site not named
Investigative Site, Italy
Site not named
Investigative Site, Malaysia
Site not named
Investigative Site, Mexico
Site not named
Investigative Site, Netherlands
Site not named
Investigative Site, Norway
Site not named
Investigative Site, Peru
Site not named
Investigative Site, Poland
Site not named
Investigative Site, Russia
Site not named
Investigative Site, Singapore
Site not named
Investigative Site, Slovakia
Site not named
Investigative Site, South Africa
Site not named
Investigative Site, Spain
Site not named
Investigative Site, Sweden
Site not named
Investigative Site, Switzerland
Site not named
Investigative Site, Taiwan
Site not named
Investigative Site, Turkey (Türkiye)
Site not named
Investigative Site, United Kingdom
Site not named
Investigative Site, Uruguay
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.